Lexeo Therapeutics (NASDAQ:LXEO) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Lexeo Therapeutics (NASDAQ:LXEO) in a research report report published on Monday, Marketbeat reports. The firm issued an overweight rating and a $19.00 price target on the stock.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Guggenheim initiated coverage on Lexeo Therapeutics in a research note on Wednesday, October 15th. They set a “buy” rating and a $30.00 target price on the stock. Leerink Partners boosted their price target on Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. HC Wainwright restated a “buy” rating on shares of Lexeo Therapeutics in a research note on Monday, November 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research report on Wednesday, October 8th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $18.63.

Lexeo Therapeutics Price Performance

LXEO opened at $8.67 on Monday. The firm has a market cap of $632.90 million, a P/E ratio of -3.21 and a beta of 1.76. Lexeo Therapeutics has a 1-year low of $1.45 and a 1-year high of $10.38. The company has a 50 day simple moving average of $8.66 and a two-hundred day simple moving average of $5.85.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.15. Equities analysts anticipate that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Insider Activity

In related news, CEO Richard Nolan Townsend sold 13,133 shares of the business’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $117,409.02. Following the sale, the chief executive officer owned 242,118 shares in the company, valued at approximately $2,164,534.92. The trade was a 5.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tai Sandi See sold 3,888 shares of the company’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $34,758.72. Following the sale, the insider directly owned 65,862 shares in the company, valued at approximately $588,806.28. The trade was a 5.57% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 24,646 shares of company stock worth $221,037. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Lexeo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of LXEO. Nuveen LLC purchased a new position in Lexeo Therapeutics during the first quarter worth $125,000. Ground Swell Capital LLC bought a new stake in shares of Lexeo Therapeutics in the 1st quarter worth about $80,000. Affinity Asset Advisors LLC bought a new stake in shares of Lexeo Therapeutics in the 1st quarter worth about $5,139,000. AQR Capital Management LLC boosted its stake in shares of Lexeo Therapeutics by 370.0% during the 1st quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock worth $175,000 after purchasing an additional 39,627 shares during the period. Finally, Millennium Management LLC grew its holdings in Lexeo Therapeutics by 654.8% during the 1st quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock valued at $3,718,000 after purchasing an additional 929,538 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.